Ravindra K Rawal

List of Publications by Year
in descending order

97	3,531	182225 30	169272 56
papers	citations	h-index	g-index

107	107	107	4945
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases. Journal of Molecular Structure, 2022, 1250, 131756.	1.8	16
2	Identifying novel putative ERK1/2 inhibitors via hybrid scaffold hopping â€“FBDD approach. Journal of Biomolecular Structure and Dynamics, 2021, , 1-16.	2.0	8
3	Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits. Expert Review of Anti-Infective Therapy, 2021, 19, 1245-1258.	2.0	8
4	Synthetic and Medicinal Perspective of Fused-Thiazoles as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 1379-1402.	0.9	21
5	Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy. Current Molecular Pharmacology, 2021, 14, 350-366.	0.7	9
6	Structure based designing of thiazolidinone-pyrimidine derivatives as ERK2 inhibitors: Synthesis and in vitro evaluation. SAR and QSAR in Environmental Research, 2021, 32, 793-816.	1.0	2
7	Agonist, antagonist and signaling modulators of ABA receptor for agronomic and post-harvest management. Plant Physiology and Biochemistry, 2020, 148, 10-25.	2.8	26
8	Identifying the mechanisms of Î±-synuclein-mediated cytotoxicity in Parkinsonâ€™s disease: new insights from a bioinformatics-based approach. Future Neurology, 2020, 15, .	0.9	4
9	Green synthetic strategies toward thiazoles: a sustainable approach. Chemistry of Heterocyclic Compounds, 2020, 56, 445-454.	0.6	12
10	CuI/DBUâ€Mediated MBH Reaction of Isatins: A Convenient Synthesis of 3â€Substitutedâ€3â€hydroxyâ€2â€oxindole. ChemistrySelect, 2020, 5, 3048-3051.	0.7	12
11	An update on chemical classes targeting ERK1/2 for the management of cancer. Future Medicinal Chemistry, 2020, 12, 593-611.	1.1	7
12	Development and characterisation of clobetasol propionate loaded Squarticles as a lipid nanocarrier for treatment of plaque psoriasis. Journal of Microencapsulation, 2020, 37, 341-354.	1.2	13
13	A Summary of Viral Targets and Recently Released PDB IDs of SARS-CoV-2. The Open Virology Journal, 2020, 14, 7-8.	1.8	3
14	Genus Calotropis: A Hub of Medicinally Active Phytoconstituents. Current Traditional Medicine, 2020, 6, 312-331.	0.1	7
15	Isolation of Sinapic Acid from Habenaria intermedia D. Don: A New Chemical Marker for the Identification of Adulteration and Substitution. Current Traditional Medicine, 2020, 6, 380-387.	0.1	4
16	Diversified Synthetic Strategies for Pyrroloindoles: An Overview. Journal of Heterocyclic Chemistry, 2019, 56, 2318-2332.	1.4	17
17	Role of sulphur-heterocycles in medicinal chemistry: An update. European Journal of Medicinal Chemistry, 2019, 180, 486-508.	2.6	226
18	Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer. Mini-Reviews in Medicinal Chemistry, 2019, 19, 1443-1458.	1.1	16

#	Article	IF	Citations
19	Structure Based Drug Design: Clinically Relevant HIV-1 Integrase Inhibitors. Current Topics in Medicinal Chemistry, 2019, 18, 2664-2680.	1.0	10
20	Diversity-Oriented Synthetic Approaches for Furoindoline: A Review. Current Organic Synthesis, 2019, 16, 342-368.	0.7	14
21	Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1936-1951.	0.9	21
22	Molecular Docking Studies on Isocytosine Analogues as Xanthine Oxidase Inhibitors. Drug Research, 2018, 68, 395-402.	0.7	9
23	RP-HPLC and UV Method Development for Simultaneous Estimation of Doxofylline, Montelukast and Levocetirizine Dihydrochloride in Pharmaceutical Dosages Form. Analytical Chemistry Letters, 2018, 8, 195-204.	0.4	1
24	Oxaliplatin for Colorectal Cancer Therapy: A Review. Clinical Cancer Drugs, 2018, 5, 13-27.	0.3	5
25	Development and Validation of UV-Spectrophotometric and RP-HPLC Methods for Simultaneous Estimation of Fexofenadine Hydrochloride, Montelukast Sodium and Ambroxol Hydrochloride in Tablet Dosage Form. Analytical Chemistry Letters, 2018, 8, 829-843.	0.4	5
26	Natural products and their derivatives as cyclooxygenase-2 inhibitors. Future Medicinal Chemistry, 2018, 10, 2471-2492.	1.1	23
27	Metal-catalyzed synthetic strategies toward coumarin derivatives. Chemistry of Heterocyclic Compounds, 2018, 54, 280-291.	0.6	17
28	Drug metabolizing enzymes and their inhibitors' role in cancer resistance. Biomedicine and Pharmacotherapy, 2018, 105, 53-65.	2.5	73
29	Applications of various analytical techniques in quality control of pharmaceutical excipients. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 122-136.	1.4	35
30	Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes. European Journal of Medicinal Chemistry, 2018, 157, 503-526.	2.6	47
31	Polysaccharides based nanomaterials for targeted anti-cancer drug delivery. Journal of Drug Targeting, 2017, 25, 1-16.	2.1	89
32	Î²-CD/CuI catalyzed regioselective synthesis of iodo substituted 1,2,3-triazoles, imidazo[1,2-a]-pyridines and benzoimidazo[2,1-b]thiazoles in water and their functionalization. Tetrahedron, 2017, 73, 4295-4306.	1.0	31
33	Design, synthesis and biological evaluation of hydrazone derivatives as anti-proliferative agents. Medicinal Chemistry Research, 2017, 26, 1459-1468.	1.1	5
34	A Highly Stereoselective Chiral Auxiliaryâ€assisted Reductive Cyclization to Furoindoline. Journal of Heterocyclic Chemistry, 2017, 54, 2696-2702.	1.4	10
35	Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review. European Journal of Medicinal Chemistry, 2017, 132, 108-134.	2.6	193
36	Synthetic and medicinal perspective of thiazolidinones: A review. Bioorganic Chemistry, 2017, 75, 406-423.	2.0	127

#	Article	IF	Citations
37	Recent synthetic and medicinal perspectives of tryptanthrin. Bioorganic and Medicinal Chemistry, 2017, 25, 4533-4552.	1.4	112
38	First report of isolation of maleamic acid from natural source Polygonatum cirrhifoliumâ€"A potential chemical marker for identification. Journal of Liquid Chromatography and Related Technologies, 2017, 40, 1031-1036.	0.5	3
39	Synthesis, characterization and pharmacological evaluation of (Z)-2-(5-(biphenyl-4-yl)-3-(1-(imino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-yl)phenol derivatives as potent antimicrobial and antioxidant agents. Arabian Journal of Chemistry, 2017, 10, S1022-S1031.	2.3	17
40	Chemical and Medicinal Versatility of Substituted 1,4-Dihydropyridines. Current Bioactive Compounds, 2017, 13, 109-120.	0.2	19
41	ICP-MS: Analytical Method for Identification and Detection of Elemental Impurities. Current Drug Discovery Technologies, 2017, 14, 106-120.	0.6	37
42	A convenient synthesis of 4-alkyl-3-benzoylpyrroles from Î±,Î²-unsaturated ketones and tosylmethyl isocyanide. Tetrahedron Letters, 2016, 57, 2315-2319.	0.7	23
43	In(OTf)₃catalysed an expeditious synthesis of Î²-carbolineâ€"imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine conjugates. RSC Advances, 2016, 6, 43881-43891.	1.7	28
44	In(OTf)₃â€HBF₄ Assisted Multicomponent Approach for Oneâ€Pot Synthesis of Pyrazolopyridinone Fused Imidazopyridines. ChemistrySelect, 2016, 1, 4696-4703.	0.7	20
45	Water-Promoted Regiospecific Azidolysis and Copper-Catalyzed Azideâ€"Alkyne Cycloaddition: One-Pot Synthesis of 3-Hydroxy-1-alkyl-3-[(4-aryl/alkyl-1H-1,2,3-triazol-1-yl)methyl]indolin-2-ones. Journal of Organic Chemistry, 2016, 81, 9757-9764.	1.7	40
46	Natural product inspired design and synthesis of Î²-carboline and Î³-lactone based molecular hybrids. Organic and Biomolecular Chemistry, 2016, 14, 8154-8166.	1.5	31
47	AlCl₃/Cyclohexane Mediated Electrophilic Activation of Isothiocyanates: An Efficient Synthesis of Thioamides. ChemistrySelect, 2016, 1, 3228-3231.	0.7	18
48	ZrCl₄ Catalysed Diastereoselective Synthesis of Spirocarbocyclic Oxindoles via [4+2] Cycloaddition. ChemistrySelect, 2016, 1, 2409-2412.	0.7	12
49	Metal-free 1,3-dipolar cycloaddition approach towards the regioselective synthesis of Î²-carboline and isoxazole based molecular hybrids. RSC Advances, 2016, 6, 88066-88076.	1.7	12
50	Impact of Artificial Neural Networks in QSAR and Computational Modeling. , 2016, , 153-179.		15
51	Chemistry and Bioactivities of Aristeromycins: An Overview. Current Topics in Medicinal Chemistry, 2016, 16, 3258-3273.	1.0	16
52	Medicinal Attributes of Imidazo[1,2-a]pyridine Derivatives: An Update. Current Topics in Medicinal Chemistry, 2016, 16, 2963-2994.	1.0	92
53	Synthetic and Medicinal Prospective of Structurally Modified Curcumins. Current Topics in Medicinal Chemistry, 2016, 17, 148-161.	1.0	30
54	Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA. Scientia Pharmaceutica, 2015, 83, 599-610.	0.7	2

#	Article	IF	Citations
55	Recent Advances in the Chemistry and Biology of Benzothiazoles. Archiv Der Pharmazie, 2015, 348, 155-178.	2.1	109
56	Riociguat as a treatment regime for pulmonary arterial hypertension: a review. Clinical and Experimental Hypertension, 2015, 37, 323-331.	0.5	1
57	Application of RPâ€“HPLC method in dissolution testing and statistical evaluation by NASSAM for simultaneous estimation of tertiary combined dosages forms. Journal of Pharmaceutical Analysis, 2015, 5, 307-315.	2.4	9
58	The critical role of bisphosphonates to target bone cancer metastasis: an overview. Journal of Drug Targeting, 2015, 23, 1-15.	2.1	66
59	Diversity-oriented synthesis of fused-imidazole derivatives via Groebkeâ€“Blackburnâ€“Bienayme reaction: a review. Tetrahedron, 2015, 71, 183-232.	1.0	114
60	Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance. Current Medicinal Chemistry, 2015, 22, 3922-3932.	1.2	10
61	Recent Advances in Polymer Drug Conjugates. Mini-Reviews in Medicinal Chemistry, 2015, 15, 751-761.	1.1	8
62	A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib. Anti-Cancer Agents in Medicinal Chemistry, 2014, 15, 37-47.	0.9	37
63	Chemometrics: A new scenario in herbal drug standardization. Journal of Pharmaceutical Analysis, 2014, 4, 223-233.	2.4	130
64	Design, synthesis and ex-vivo release studies of colon-specific polyphosphazeneâ€“anticancer drug conjugates. Bioorganic and Medicinal Chemistry, 2014, 22, 1104-1114.	1.4	28
65	Chemometrics tools used in analytical chemistry: An overview. Talanta, 2014, 123, 186-199.	2.9	288
66	A Comprehensive Review on Combretastatin Analogues as Tubulin Binding Agents. Current Organic Chemistry, 2014, 18, 2462-2512.	0.9	21
67	A Compendium of Techniques for the Analysis of Pharmaceutical Impurities. Current Pharmaceutical Analysis, 2014, 10, 145-160.	0.3	4
68	A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir. Current HIV Research, 2014, 12, 325-338.	0.2	5
69	2â€²-Fluoro-6â€²-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: In vitro anti-HBV activity against the lamivudineâ€“entecavir resistant triple mutant and its mechanism of action. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 503-506.	1.0	15
70	Design, synthesis and ex vivo evaluation of colon-specific azo based prodrugs of anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5332-5338.	1.0	30
71	Synthesis and Characterization of 3β.-Substituted Amides of 17a-Aza-Dhomo- 4-androsten-17-one as Potent 5.α-Reductase Inhibitors and Antimicrobial Agents. Current Topics in Medicinal Chemistry, 2013, 13, 2047-2061.	1.0	2
72	Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group. Letters in Drug Design and Discovery, 2013, 10, 872-878.	0.4	5

#	Article	IF	Citations
73	Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIs. Current Medicinal Chemistry, 2012, 19, 5364-5380.	1.2	30
74	Synthesis of Entecavir and Its Novel Class of Analogs. Current Protocols in Nucleic Acid Chemistry, 2011, 47, Unit 14.7.1-17.	0.5	5
75	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood, 2011, 118, 2159-2169.	0.6	14
76	Antiviral activity of novel 2â€²-fluoro-6â€²-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6328-6331.	1.0	13
77	Synthesis and antiviral activity of cyclopropyl-spirocarbocyclic adenosine, (4 R ,5 S ,6 R ,7 R) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3982-3985.	1.0	21
78	Structureâ€“activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorganic and Medicinal Chemistry, 2010, 18, 3403-3412.	1.4	16
79	(â^)-Carbodine: Enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2601-2604.	1.0	10
80	Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine, 2010, 28, 1547-1557.	1.7	42
81	Mamu-AâŽ01/Kb transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. Virology, 2009, 387, 16-28.	1.1	2
82	Breaking Immune Tolerance to Granule Proteases with Full-Length Antigen Vaccine in Humanized Transgenic Mice Reveals Alternative Antigen Processing and Immunodominance Heirarchy Applicable to Clinical Immunotherapy.. Blood, 2009, 114, 2054-2054.	0.6	0
83	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. European Journal of Medicinal Chemistry, 2008, 43, 2800-2806.	2.6	97
84	A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. Immunology Letters, 2008, 120, 108-116.	1.1	8
85	Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-Aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6110-6114.	1.0	36
86	2â€(2,6â€Dihaloâ€phenyl)â€3â€heteroarylâ€2â€ylmethylâ€1, 3â€thiazolidinâ€4â€ones: Antiâ€HIV agents. Chemical Biology and Drug Design, 2008, 72, 147-154.	1.5	21
87	Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorganic and Medicinal Chemistry, 2007, 15, 1725-1731.	1.4	164
88	Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorganic and Medicinal Chemistry, 2007, 15, 3134-3142.	1.4	119
89	Molecular Surface Features in Modeling the HIV-1 RT Inhibitory Activity of 2-(2,6-Disubstituted) Tj ETQq1 1 0.784314 rgBT /Overlock 1 398-406.	1.5	11
90	Synthesis and Biological Evaluation of 2, 3-Diaryl substituted-1, 3-thiazolidin-4-ones as Anti-HIV Agents. Medicinal Chemistry, 2007, 3, 355-363.	0.7	22

#	Article	IF	Citations
91	2-(2,6-Dichlorophenyl)-3-(quinolin-2-yl)thiazolidin-4-one. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o5349-o5351.	0.2	1
92	Molecular docking studies on 4-thiazolidinones as HIV-1 RT inhibitors. Journal of Molecular Modeling, 2006, 13, 155-161.	0.8	21
93	2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT Inhibitors. Bioorganic and Medicinal Chemistry, 2005, 13, 6771-6776.	1.4	158
94	Synthesis and QSAR Studies on Thiazolidinones as Anti-HIV Agents. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 439-443.	0.6	28
95	Topological Descriptors in Modeling the HIV Inhibitory Activity of 2-Aryl-3- pyridyl-thiazolidin-4-ones. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 431-437.	0.6	36
96	An expeditious synthesis of thiazolidinones and tetathiazanones. Journal of Chemical Research, 2004, 2004, 368-369.	0.6	51
97	CP-MLR/PLS Directed Structure-Activity Modeling of the HIV-1 RT Inhibitory Activity of 2,3-Diaryl-1,3-thiazolidin-4-ones. QSAR and Combinatorial Science, 2004, 23, 234-244.	1.5	58